Manuel Cossio

Head of AI Solutions, Real-World Evidence, Value, and Access

Manuel Cossio is Head of AI Solutions, Real-World Evidence, Value, and Access at Cytel. Manuel is an AI engineer with over a decade of experience in healthcare AI research and development. He currently leads the creation of generative AI solutions aimed at optimizing clinical trials, focusing on hierarchical multi-agent systems with multistage data governance and human-in-the-loop dynamic behavior control.

Manuel has an extensive research background with publications in computer vision, natural language processing, and genetic data analysis. He is a registered Key Opinion Leader at the Digital Medicine Society, a member of the ISPOR Community of Interest in AI, a Generative AI evaluator for the EU Commission, and an AI researcher at UB-UPC- Barcelona Supercomputing Center.

He holds an M.Sc. in Translational Medicine from Universitat de Barcelona, a Master of Engineering in AI from Universitat Politècnica de Catalunya, and a M.Sc. in Neuroscience from Universitat Autònoma de Barcelona.

Manuel Cossio

Related Articles

The Evolving Role of AI in Oncology: Insights from ESMO 2026
Blog
October 30, 2026
The Evolving Role of AI in Oncology: Insights from ESMO 2026
Read More
Why More AI is Not Always Better for Clinical Programming
Blog
October 20, 2026
Why More AI is Not Always Better for Clinical Programming
Read More
Office Hours – AI, Evidence, Regulatory and HTA Expectations
Office Hours
November 3, 2026
Office Hours – AI, Evidence, Regulatory and HTA Expectations
Read More
NICE’s AI Delivery Plan: What HTA, HEOR, and Market Access Professionals Need to Know
Blog
September 23, 2026
NICE’s AI Delivery Plan: What HTA, HEOR, and Market Access Professionals Need to Know
Read More
Webinar – Token Efficient Clinical Programming Through Hybrid Agentic AI and Rule-Based Systems
Webinar
September 24, 2026
Webinar – Token Efficient Clinical Programming Through Hybrid Agentic AI and Rule-Based Systems
Read More
From Principles to Practice: What Global Regulators and HTA Agencies Are Saying About AI in Medicines Development and Evidence Generation
Blog
September 15, 2026
From Principles to Practice: What Global Regulators and HTA Agencies Are Saying About AI in Medicines Development and Evidence Generation
Read More